Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | ADPT | Common Stock | Options Exercise | $93.6K | +14.8K | +0.77% | $6.32 | 1.93M | Mar 7, 2022 | Direct | F1 |
transaction | ADPT | Common Stock | Sale | -$6.11K | -500 | -0.03% | $12.22 | 1.93M | Mar 7, 2022 | Direct | F1, F2 |
transaction | ADPT | Common Stock | Sale | -$165K | -14.3K | -0.74% | $11.53 | 1.92M | Mar 7, 2022 | Direct | F1, F3 |
transaction | ADPT | Common Stock | Options Exercise | -$93.6K | -14.8K | -0.76% | $6.32 | 1.93M | Mar 8, 2022 | Direct | F1 |
transaction | ADPT | Common Stock | Sale | -$169K | -14.8K | -0.77% | $11.38 | 1.92M | Mar 8, 2022 | Direct | F1, F4 |
transaction | ADPT | Common Stock | Options Exercise | -$93.6K | -14.8K | -0.76% | $6.32 | 1.93M | Mar 9, 2022 | Direct | F1 |
transaction | ADPT | Common Stock | Sale | -$185K | -14.8K | -0.77% | $12.46 | 1.92M | Mar 9, 2022 | Direct | F1, F5 |
Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | ADPT | Stock Option (Right to Buy) | Options Exercise | $0 | -14.8K | -1.85% | $0.00 | 785K | Mar 7, 2022 | Common Stock | 14.8K | $6.32 | Direct | F1, F6 |
transaction | ADPT | Stock Option (Right to Buy) | Options Exercise | $0 | -14.8K | -1.89% | $0.00 | 770K | Mar 8, 2022 | Common Stock | 14.8K | $6.32 | Direct | F1, F6 |
transaction | ADPT | Stock Option (Right to Buy) | Options Exercise | $0 | -14.8K | -1.92% | $0.00 | 756K | Mar 9, 2022 | Common Stock | 14.8K | $6.32 | Direct | F1, F6 |
Id | Content |
---|---|
F1 | The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2021. |
F2 | The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $12.21 to 12.24, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. |
F3 | The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $11.21 to 12.20, inclusive. |
F4 | The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $11.27 to 11.55, inclusive. |
F5 | The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $12.21 to 12.73, inclusive. |
F6 | The option is fully vested and exercisable. |